AMETEK Acquires LKC, Sharpening Focus on Ophthalmic Diagnostics

BERWYN, PA – February 03, 2026 – Industrial technology giant AMETEK, Inc. (NYSE: AME) today announced a significant expansion of its medical portfolio with the acquisition of LKC Technologies, a specialized innovator in ophthalmic diagnostic devices. The move, confirmed in a press release, positions AMETEK to capitalize on the growing demand for early detection of serious eye conditions like diabetic retinopathy.

LKC Technologies, based in Germantown, MD, will be integrated into AMETEK's Electronic Instruments Group (EIG), specifically aligning with its Ultra Precision Technologies Reichert business. While financial terms of the deal were not disclosed, the acquisition is a clear strategic play to broaden AMETEK’s footprint in the high-growth medical technology sector.

A Strategic Vision for Growth

For AMETEK, a global provider of industrial solutions with approximately $7.5 billion in annual sales, this acquisition is a textbook execution of its long-standing growth model. The company’s framework, which combines Operational Excellence, Technology Innovation, and Global Expansion, heavily emphasizes Strategic Acquisitions as a key pillar for achieving its goal of double-digit earnings per share growth.

David A. Zapico, AMETEK Chairman and Chief Executive Officer, underscored the strategic alignment in the official announcement. "We are excited to welcome LKC Technologies to AMETEK," he stated. "LKC Technologies is an excellent strategic fit with our Ultra Precision Technologies Reichert business, providing attractive market expansion opportunities and creating a broader ophthalmic product portfolio."

The integration with Reichert is designed to create powerful synergies. By combining AMETEK’s extensive engineering resources and global market reach with LKC’s specialized diagnostic expertise, the company aims to accelerate innovation in patient eye care. LKC's established presence in visual electrophysiology provides a new, highly specialized capability for AMETEK's existing medical segment. This move signals a deliberate push into more advanced, clinically-focused diagnostic instrumentation.

Transforming Diagnostics at the Point of Care

At the heart of this acquisition is LKC Technologies' innovative product line, led by its flagship device, the RETeval Electroretinography (ERG) system. This handheld, FDA-cleared device represents a significant leap forward in making complex functional eye testing accessible and efficient.

Traditionally, ERG testing, which measures the electrical response of the eye's light-sensitive cells, has been a cumbersome procedure confined to specialized hospital settings. LKC's RETeval revolutionizes this process. Its key innovations include:

• Portability and Ease of Use: The handheld design allows for testing in virtually any clinical setting, from a standard ophthalmologist's office to primary care clinics and remote screening locations.
• Non-Invasive Technology: The device utilizes disposable skin electrodes placed on the face, eliminating the need for uncomfortable corneal electrodes that touch the eye itself.
• Rapid, Objective Results: RETeval can perform tests on undilated pupils in under three minutes, providing immediate, objective data on retinal function.

This technology is particularly crucial for the early detection of diabetic retinopathy, a leading cause of blindness in working-age adults. Clinical studies have validated the RETeval as a fast and effective screening tool, demonstrating a lower technical failure rate than traditional imaging methods, which can be hampered by issues like small pupils or cataracts. With the backing of over 250 peer-reviewed publications, LKC's technology provides a functional assessment of retinal health, complementing the structural information provided by imaging.

Zapico noted the potential for collaborative advancement, stating, "We look forward to leveraging our respective design and engineering capabilities to further advance patient eye healthcare together." This suggests that AMETEK's engineering prowess could help scale production, refine features, and potentially integrate LKC's technology into broader health data platforms.

Consolidation in a Niche Medical Market

The AMETEK-LKC deal is a microcosm of a larger trend in the medical device industry: the strategic acquisition of niche innovators by large, diversified corporations. Companies like LKC, with over 35 years of focused R&D in visual electrophysiology, develop highly specialized, high-value technology that can be difficult for larger entities to replicate internally.

By acquiring LKC, AMETEK bypasses the lengthy and resource-intensive process of developing a new product category from scratch. Instead, it gains a market-proven technology, an established intellectual property portfolio, and deep domain expertise. This "buy-versus-build" strategy allows industrial giants to quickly enter and compete in lucrative, high-growth medical segments.

The acquisition places AMETEK in a more competitive position against established ophthalmic diagnostic players like Carl Zeiss Meditec, Topcon, and Nidek. While these companies offer broad portfolios of imaging and refractive devices, LKC’s specialization in functional electrophysiology provides a unique and complementary diagnostic tool. Bolstered by AMETEK's formidable global sales and distribution network, the RETeval and other LKC products are poised for significantly wider market penetration. This could pressure competitors to either develop similar functional testing capabilities or seek their own strategic acquisitions to keep pace.

Market Outlook and Future Impact

The timing of the acquisition is particularly astute. The market for ophthalmic diagnostics is being driven by powerful tailwinds, including the rising global prevalence of diabetes and an aging population more susceptible to eye diseases. Furthermore, the healthcare industry's shift toward preventative medicine and point-of-care diagnostics creates a fertile ground for technologies like the RETeval.

The private equity firm DW Healthcare Partners, which sold LKC to AMETEK, noted it had spent the last three years helping the company scale its operations and raise awareness for its unique technology. The sale to a strategic buyer like AMETEK is seen as the next logical step in LKC’s growth trajectory.

For investors, while the immediate financial impact remains unquantified without a purchase price, the strategic rationale is clear. The move aligns with AMETEK's proven M&A strategy of acquiring differentiated businesses in attractive niche markets. The company, with a market capitalization of over $51 billion, has the resources to fully integrate LKC and exploit the market opportunities ahead. The successful integration and scaling of LKC's technology could provide a meaningful contribution to AMETEK’s Electronic Instruments Group and solidify its position as a key player in the future of eye health diagnostics.